2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2022-002348-33-ES (EUCTR) | 22/12/2022 | 27/09/2022 | A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX) | A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX) | ALS (amyotrophic lateral sclerosis) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: AMX0035 INN or Proposed INN: PHENYLBUTYRATE Other descriptive name: PHENYLBUTYRATE INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol | Amylyx Pharmaceuticals Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | Portugal;France;United States;Belgium;Poland;Spain;Ireland;Germany;Netherlands;United Kingdom;Italy;Sweden | ||
| 2 | EUCTR2022-002348-33-NL (EUCTR) | 06/12/2022 | 11/10/2022 | A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-0 | A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX) | ALS (amyotrophic lateral sclerosis) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: AMX0035 INN or Proposed INN: PHENYLBUTYRATE Other descriptive name: PHENYLBUTYRATE INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol | Amylyx Pharmaceuticals Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | Portugal;France;United States;Belgium;Spain;Poland;Ireland;Germany;Netherlands;United Kingdom;Italy;Sweden | ||
| 3 | NCT05286372 (ClinicalTrials.gov) | September 23, 2022 | 9/3/2022 | An Intermediate Size Expanded Access Protocol of AMX0035 for ALS | An Intermediate Size, Expanded Access Protocol to Provide AMX0035, a Fixed Combination of Sodium Phenylbutyrate (PB) and Taurursodiol (TURSO), for the Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: AMX0035 | Amylyx Pharmaceuticals Inc. | NULL | Approved for marketing | 18 Years | N/A | All | United States;Puerto Rico | ||
| 4 | EUCTR2021-000250-26-PT (EUCTR) | 29/04/2022 | 08/10/2021 | A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix | ALS (amyotrophic lateral sclerosis) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: AMX0035 INN or Proposed INN: phenylbutyrate INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol Product Code: AMX0035 INN or Proposed INN: PHENYLBUTYRATE INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol | Amylyx Pharmaceuticals Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | France;United States;Portugal;Spain;Poland;Belgium;Ireland;Netherlands;Germany;United Kingdom;Italy;Sweden | ||
| 5 | EUCTR2021-000250-26-PL (EUCTR) | 23/02/2022 | 22/11/2021 | A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix | ALS (amyotrophic lateral sclerosis) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: AMX0035 INN or Proposed INN: phenylbutyrate INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol | Amylyx Pharmaceuticals Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | Portugal;France;United States;Belgium;Spain;Poland;Ireland;Germany;Netherlands;United Kingdom;Italy;Sweden | ||
| 6 | ChiCTR2100051913 | 2021-12-31 | 2021-10-09 | Sodium Phenylbutyrate Granules Combined with Tauroursodeoxycholic Acid Capsules for Amyotrophic Lateral Sclerosis: A Multicentre, Randomised, Double-blind, Placebo-controlled Clinical Trial | Sodium Phenylbutyrate Granules Combined with Tauroursodeoxycholic Acid Capsules for Amyotrophic Lateral Sclerosis: A Multicentre, Randomised, Double-blind, Placebo-controlled Clinical Trial | Amyotrophic lateral sclerosis | Experimental group:Sodium phenylbutyrate granules + tauroursodeoxycholic acid capsules;Control group:Sodium phenylbutyrate placebo + tauroursodeoxycholic acid placebo; | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | NULL | Pending | 18 | 80 | Both | Experimental group:136;Control group:68; | N/A | China |
| 7 | EUCTR2021-000250-26-IT (EUCTR) | 14/12/2021 | 18/10/2021 | A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix | ALS (amyotrophic lateral sclerosis);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AMX0035 Product Code: [AMX0035] INN or Proposed INN: Sodio phenylbutyrate INN or Proposed INN: Tauroursodeoxycholic Acid | AMYLYX PHARMACEUTICALS Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | Portugal;France;United States;Spain;Poland;Belgium;Ireland;Netherlands;Germany;United Kingdom;Italy;Sweden | ||
| 8 | EUCTR2021-000250-26-FR (EUCTR) | 22/11/2021 | 25/06/2021 | A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix | ALS (amyotrophic lateral sclerosis) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: AMX0035 INN or Proposed INN: phenylbutyrate INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol Product Code: AMX0035 INN or Proposed INN: PHENYLBUTYRATE INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol | Amylyx Pharmaceuticals Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | Portugal;United States;France;Spain;Poland;Belgium;Ireland;Netherlands;Germany;United Kingdom;Italy;Sweden | ||
| 9 | EUCTR2021-000250-26-DE (EUCTR) | 27/10/2021 | 22/06/2021 | A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix | ALS (amyotrophic lateral sclerosis) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: AMX0035 INN or Proposed INN: phenylbutyrate INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol | Amylyx Pharmaceuticals Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | Portugal;France;United States;Spain;Poland;Belgium;Ireland;Netherlands;Germany;United Kingdom;Italy;Sweden | ||
| 10 | EUCTR2021-000250-26-NL (EUCTR) | 03/09/2021 | 06/07/2021 | A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix | ALS (amyotrophic lateral sclerosis) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: AMX0035 INN or Proposed INN: phenylbutyrate INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol Product Code: AMX0035 INN or Proposed INN: PHENYLBUTYRATE INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol | Amylyx Pharmaceuticals Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | Portugal;France;United States;Spain;Poland;Belgium;Ireland;Germany;Netherlands;United Kingdom;Italy;Sweden | ||
| 11 | EUCTR2021-000250-26-SE (EUCTR) | 26/08/2021 | 28/06/2021 | A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - Phoenix | ALS (amyotrophic lateral sclerosis) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: AMX0035 INN or Proposed INN: phenylbutyrate INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol Product Code: AMX0035 INN or Proposed INN: PHENYLBUTYRATE INN or Proposed INN: Ursodoxicoltaurine Other descriptive name: taurursodiol | Amylyx Pharmaceuticals Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | Portugal;France;United States;Spain;Poland;Belgium;Ireland;Netherlands;Germany;United Kingdom;Italy;Sweden | ||
| 12 | NCT03127514 (ClinicalTrials.gov) | June 22, 2017 | 12/4/2017 | AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS | Amyotrophic Lateral Sclerosis;Motor Neuron Disease;Neuromuscular Diseases;Neurodegenerative Diseases;Spinal Cord Diseases;TDP-43 Proteinopathies;Nervous System Diseases;Central Nervous System Diseases | Drug: AMX0035;Other: Placebo | Amylyx Pharmaceuticals Inc. | ALS Finding a Cure Foundation;ALS Association;Northeast ALS Consortium;Massachusetts General Hospital Neurology Clinical Research Institute;Leandro P. Rizzuto Foundation | Completed | 18 Years | 80 Years | All | 137 | Phase 2/Phase 3 | United States |
| 13 | NCT00107770 (ClinicalTrials.gov) | April 2005 | 7/4/2005 | Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis) | Safety and Dose Escalating Study of Oral Sodium Phenylbutyrate in Subjects With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: sodium phenylbutyrate | Department of Veterans Affairs | Muscular Dystrophy Association | Completed | 18 Years | N/A | Both | 40 | Phase 1/Phase 2 | United States |